IN2014MN00377A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00377A
IN2014MN00377A IN377MUN2014A IN2014MN00377A IN 2014MN00377 A IN2014MN00377 A IN 2014MN00377A IN 377MUN2014 A IN377MUN2014 A IN 377MUN2014A IN 2014MN00377 A IN2014MN00377 A IN 2014MN00377A
Authority
IN
India
Prior art keywords
complex
metalloproteinase inhibitor
relates
renal
kda
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of IN2014MN00377A publication Critical patent/IN2014MN00377A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
IN377MUN2014 2011-08-26 2012-08-24 IN2014MN00377A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528000P 2011-08-26 2011-08-26
US201161528003P 2011-08-26 2011-08-26
PCT/US2012/052298 WO2013043310A1 (en) 2011-08-26 2012-08-24 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
IN2014MN00377A true IN2014MN00377A (ko) 2015-06-19

Family

ID=47914751

Family Applications (1)

Application Number Title Priority Date Filing Date
IN377MUN2014 IN2014MN00377A (ko) 2011-08-26 2012-08-24

Country Status (16)

Country Link
US (2) US9459261B2 (ko)
EP (2) EP2748605B1 (ko)
JP (2) JP2014529073A (ko)
KR (1) KR20140074307A (ko)
CN (2) CN103874923B (ko)
AU (1) AU2012312907A1 (ko)
BR (1) BR112014004389A2 (ko)
CA (1) CA2846602A1 (ko)
EA (1) EA201490384A1 (ko)
ES (1) ES2721907T3 (ko)
IN (1) IN2014MN00377A (ko)
MX (1) MX346096B (ko)
PL (1) PL2748605T4 (ko)
PT (1) PT2748605T (ko)
TR (1) TR201903235T4 (ko)
WO (1) WO2013043310A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102246035B (zh) 2008-10-21 2014-10-22 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2784889C (en) 2009-12-20 2018-06-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140074307A (ko) * 2011-08-26 2014-06-17 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
CN107976547B (zh) 2013-01-17 2020-08-25 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
PT2759550T (pt) 2013-01-28 2018-11-16 Diasorin S P A Método e kit para detetar 1,25-di-hidroxivitamina d e anticorpos relacionados
US10983136B2 (en) 2013-01-28 2021-04-20 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
US11261257B2 (en) 2013-01-28 2022-03-01 Diasorin S.P.A. Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
EP3077819A4 (en) 2013-12-03 2017-06-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BR112017008218A2 (pt) * 2014-10-20 2018-01-09 Astute Medical Inc métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal
CA2973653A1 (en) * 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
EP3281011B1 (en) 2015-04-09 2024-06-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105466984B (zh) * 2016-01-14 2018-12-28 郑以山 用于肾脏非显性损伤的预警装置及其使用方法
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
AU2018207151B2 (en) 2017-01-12 2024-02-29 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11718682B2 (en) 2017-04-05 2023-08-08 Astute Medical, Inc. Assays for TIMP2 having improved performance in biological samples
AU2019272960A1 (en) 2018-05-24 2020-12-10 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
CN109251956A (zh) * 2018-09-18 2019-01-22 青岛大学 糖尿病大鼠胰岛内MyD88 mRNA表达及黄芪的调节作用
WO2020092909A1 (en) * 2018-11-02 2020-05-07 Prevencio, Inc. Prognostic and diagnostic methods for risk of acute kidney injury
CN114113575B (zh) * 2020-08-28 2023-06-02 菲鹏生物股份有限公司 标记复合物及其制备方法与应用
CN116434960B (zh) * 2023-06-13 2023-10-13 中国人民解放军总医院 一种心源性休克临床决策支持系统、设备及可存储介质

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
DE69228682T2 (de) 1991-04-10 1999-07-01 Biosite Diagnostics Inc., San Diego, Calif. "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
WO1992018866A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU2004225472B2 (en) * 2003-03-27 2011-02-10 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
WO2005002416A2 (en) * 2003-06-04 2005-01-13 Joslin Diabetes Center, Inc. Predictors of renal disease
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
CN101557825A (zh) * 2005-08-19 2009-10-14 森托科尔公司 抗蛋白酶解的抗体制剂
WO2007144781A2 (en) * 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
CA2681792A1 (en) * 2007-03-26 2008-10-02 Novartis Ag Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
PL2215481T5 (pl) 2007-11-15 2017-10-31 Bioporto Diagnostics As Zastosowanie diagnostyczne indywidualnych postaci cząsteczkowych biomarkera
JP4423375B2 (ja) * 2008-02-29 2010-03-03 国立大学法人名古屋大学 急性腎障害及び予後推定用バイオマーカー並びにその用途
AU2009285550B2 (en) * 2008-08-28 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2813848A3 (en) * 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102246035B (zh) * 2008-10-21 2014-10-22 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
AU2009313189B2 (en) * 2008-11-10 2014-10-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) * 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0924639B1 (pt) * 2009-06-02 2021-12-07 Biocrates Life Sciences Ag Novos biomarcadores para avaliação de doenças renais
CN102576011B (zh) * 2009-08-07 2014-09-17 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的组合物和方法
EP2470904A4 (en) * 2009-09-18 2013-05-01 Astute Medical Inc METHODS AND COMPOSITION FOR DIAGNOSIS AND PROGNOSIS OF RENAL LESION AND FAILURE
MX2009012633A (es) * 2009-11-23 2011-05-24 Univ Mexico Nacional Autonoma Metodo de diagnostico para detectar la lesion renal aguda a traves del uso de la proteina de choque termico de 72 kda como un biomarcador sensible.
CA2784889C (en) * 2009-12-20 2018-06-19 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ705411A (en) * 2010-02-26 2016-06-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140074307A (ko) * 2011-08-26 2014-06-17 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전의 진단 및 예후진단을 위한 방법 및 조성물

Also Published As

Publication number Publication date
US20140213477A1 (en) 2014-07-31
CA2846602A1 (en) 2013-03-28
MX346096B (es) 2017-03-07
NZ621716A (en) 2016-04-29
MX2014002146A (es) 2014-08-21
EP2748605B1 (en) 2018-12-05
CN106443011A (zh) 2017-02-22
US20170016917A1 (en) 2017-01-19
PL2748605T3 (pl) 2019-08-30
WO2013043310A1 (en) 2013-03-28
JP2017032586A (ja) 2017-02-09
BR112014004389A2 (pt) 2017-03-28
US9784750B2 (en) 2017-10-10
EA201490384A1 (ru) 2014-08-29
US9459261B2 (en) 2016-10-04
CN103874923A (zh) 2014-06-18
KR20140074307A (ko) 2014-06-17
JP2014529073A (ja) 2014-10-30
TR201903235T4 (tr) 2019-03-21
ES2721907T3 (es) 2019-08-06
EP2748605A4 (en) 2015-12-02
NZ706242A (en) 2016-07-29
PL2748605T4 (pl) 2019-08-30
EP2748605A1 (en) 2014-07-02
CN103874923B (zh) 2016-09-14
PT2748605T (pt) 2019-05-03
EP3489690A1 (en) 2019-05-29
AU2012312907A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
IN2014MN00377A (ko)
MX2011002233A (es) Metodos y composiciones para la diagnosis y prognosis de daño renal y falla renal.
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012174282A3 (en) Biomarker compositions and methods
EA201290387A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2014193999A3 (en) Biomarker methods and compositions
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
MX2011008323A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
EP2813848A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
EP2585827A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX2013000916A (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
MX2014000283A (es) Metodos y composiciones para diagnóstico y pronóstico de lesión e insuficiencia renal.
NZ619918A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008100352A3 (en) Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
BR112012007365A2 (pt) proteínas de ligação à il-1
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
EA201290195A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
MX339765B (es) Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
MX2012003168A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal e insuficiencia renal.
IN2014MN00949A (ko)